Comparison of blinatumomab and chimeric antigen receptor T cells pre-haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome negative B-cell acute lymphoblastic leukemiaOACSCDCSTPCD
Comparison of blinatumomab and chimeric antigen receptor T cells pre-haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome negative B-cell acute lymphoblastic leukemia
Guanhua Hu;Pan Suo;Lu Bai;Xiaohui Zhang;Yifei Cheng;Xiaojun Huang
Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,ChinaPeking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Peking-Tsinghua Center for Life Science,Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies,Chinese Academic of Medical Sciences,Beijing 100044,China
《中华医学杂志（英文版）》 2025 (4)
472-474,3
This work was supported by grants from the project(No.RDJP2022-71),Peking University People's Hospital Scientific Research Development Funds and the CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2019-12M-5-034).
评论